ADMA Biologics (ADMA) Set to Announce Quarterly Earnings on Thursday

ADMA Biologics (NASDAQ:ADMA) is scheduled to announce its earnings results after the market closes on Thursday, November 7th. Analysts expect the company to announce earnings of $0.13 per share for the quarter. ADMA Biologics has set its FY 2024 guidance at EPS and its FY 2025 guidance at EPS.Parties interested in registering for the company’s conference call can do so using this link.

ADMA Biologics (NASDAQ:ADMA) last announced its quarterly earnings results on Thursday, August 8th. The biotechnology company reported $0.13 EPS for the quarter, beating analysts’ consensus estimates of $0.08 by $0.05. The business had revenue of $107.20 million for the quarter, compared to analyst estimates of $86.44 million. ADMA Biologics had a net margin of 10.53% and a return on equity of 38.79%. ADMA Biologics’s quarterly revenue was up 78.4% on a year-over-year basis. During the same quarter in the prior year, the business earned ($0.02) EPS. On average, analysts expect ADMA Biologics to post $0 EPS for the current fiscal year and $1 EPS for the next fiscal year.

ADMA Biologics Stock Performance

ADMA stock traded down $0.36 during mid-day trading on Tuesday, hitting $18.75. 806,652 shares of the company were exchanged, compared to its average volume of 3,625,680. ADMA Biologics has a 1-year low of $3.54 and a 1-year high of $21.13. The stock has a market capitalization of $4.37 billion, a PE ratio of 136.50 and a beta of 0.64. The business has a 50 day simple moving average of $17.88 and a 200-day simple moving average of $13.56. The company has a current ratio of 6.87, a quick ratio of 2.80 and a debt-to-equity ratio of 0.74.

Wall Street Analyst Weigh In

Several analysts recently issued reports on ADMA shares. HC Wainwright restated a “buy” rating and issued a $18.00 price target on shares of ADMA Biologics in a research note on Monday, October 14th. Cantor Fitzgerald reissued an “overweight” rating and set a $20.00 target price on shares of ADMA Biologics in a report on Friday, September 20th. One research analyst has rated the stock with a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Buy” and an average price target of $15.50.

Insider Activity at ADMA Biologics

In other ADMA Biologics news, CEO Adam S. Grossman sold 236,889 shares of ADMA Biologics stock in a transaction on Monday, August 26th. The stock was sold at an average price of $17.69, for a total value of $4,190,566.41. Following the completion of the transaction, the chief executive officer now directly owns 2,059,726 shares of the company’s stock, valued at $36,436,552.94. The trade was a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In related news, CEO Adam S. Grossman sold 236,889 shares of the firm’s stock in a transaction on Monday, August 26th. The stock was sold at an average price of $17.69, for a total value of $4,190,566.41. Following the transaction, the chief executive officer now owns 2,059,726 shares in the company, valued at approximately $36,436,552.94. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Jerrold B. Grossman sold 136,861 shares of the business’s stock in a transaction dated Thursday, August 29th. The shares were sold at an average price of $17.27, for a total value of $2,363,589.47. Following the completion of the transaction, the director now directly owns 467,305 shares of the company’s stock, valued at approximately $8,070,357.35. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 466,900 shares of company stock worth $8,224,121. Company insiders own 3.70% of the company’s stock.

ADMA Biologics Company Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.